282524-82-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-3-(4-tert-butyl-phenyl)-propionic acid is used as a building block for the synthesis of pharmaceutical compounds due to its unique structure and properties. Its presence in the formation of proteins makes it a valuable component in the development of new drugs and therapeutic agents.
Used in Biochemical Research:
3-Amino-3-(4-tert-butyl-phenyl)-propionic acid is used as a research tool in the study of protein synthesis and the role of amino acids in biological processes. Its unique structure allows researchers to investigate the interactions between amino acids and other biomolecules, contributing to a better understanding of biochemical mechanisms.
Used in Nutritional Supplements:
3-Amino-3-(4-tert-butyl-phenyl)-propionic acid may be used as a component in nutritional supplements, particularly those designed to support protein synthesis and overall health. Its role in the formation of proteins makes it a potentially beneficial addition to dietary supplements for individuals seeking to improve their health and well-being.

InChI:InChI=1/C13H19NO2/c1-13(2,3)10-6-4-9(5-7-10)11(14)8-12(15)16/h4-7,11H,8,14H2,1-3H3,(H,15,16)

Upstream product

• 141-82-2 malonic acid 
• 939-97-9 4-tert-Butylbenzaldehyde 
• 98708-80-6 4'-tert-butyl-(RS)-α-phenylalanine 

Downstream Products

• 496912-08-4 3-amino-3-(4-tert-butyl-phenyl)-propionic acid ethyl ester 
• 618109-81-2 methyl 3-amino-3-(4-(tert-butyl)phenyl)propanoate 

Relevant academic research and scientific papers

Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer

Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase. eEF2K has been recently reported to be highly activated or overexpressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (21l) with best eEF2K enzymatic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM). Moreover, we found that 21l could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells. Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo. These results suggested that 21l inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436). Collectively, our results demonstrate a novel small-molecule inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.

Preparation and application of novel eEF2K depressant

The invention relates to preparation and application of an eEF2K depressant and belongs to the technical field of antitumor pharmacy. A technical problem to be solved by the invention is to provide acompound as the eEF2K depressant. The compound comprises a compound represented by a formula shown in the description or pharmaceutically acceptable salts thereof. The compound or pharmaceutically acceptable salts thereof can serve as the eEF2K depressant, have certain anti-tumor activity and can effectively depress the growth of cancer cells. The compound disclosed by the invention has an obviousdepression action on a variety of tumor cells, particularly three-negative mammary cancer cells.

Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1)

All-trans-retinoic acid (ATRA), the biologically active metabolite of vitamin A, is used medicinally for the treatment of hyperproliferative diseases and cancers. However, it is easily metabolized. In this study, the leading compound S8 was found based on virtual screening. To improve the activity of the leading compound S8, a series of novel S8 derivatives were designed, synthesized and evaluated for their in vitro biological activities. All of the prepared compounds showed that substituting the 5-chloro-3-methyl-1-phenyl-1H-pyrazole group for the 2-tertbutyl-5-methylfuran scaffold led to a clear increase in the biological activity. The most promising compound 32, with a CYP26A1 IC50 value of 1.36 μM (compared to liarozole (IC50 = 2.45 μM) and S8 (IC50 = 3.21 μM)) displayed strong inhibitory and differentiation activity against HL60 cells. In addition, the study focused on the effect of β-phenylalanine, which forms the coordination bond with the heme of CYP26A1. These studies suggest that the compound 32 can be used as an appropriate candidate for future development.

β-styryl- and β-aryl-β-alanine products of phenylalanine aminomutase catalysis

The substrate specificity of a Taxus-derived phenylalanine aminomutase (PAM) was investigated, and the enzyme was found to catalyze the conversion of variously substituted vinyl- and aryl-S-∞-alanines to corresponding β-amino acids. This study shows the b

PROCESS FOR THE PREPARATION OF β-AMINOCARBOXYLIC ACIDS

The present invention relates to a method of producing β-aminocarboxylic acids or their derivatives by conversion of compounds of formula (I) with ketene acetals in the presence of a base.

Aromatic β-amino acids as Asp-Phg mimics in LDV derived VLA-4 antagonists

Aromatic β-amino acid esters 2a-h were prepared in racemic and enantiomerically pure form by the Radionow reaction or based on the method described by Davis and used as mimics of the Asp-Phg C-terminus in LDV derived VLA-4 antagonists. As a promising β-am